Pharma stock jumps after firm with the help of Gates Foundation to develop vaccine for typhoid for children
News by Aliceblue News Desk
04 Mar 2025
Introduction:
Leading pharma company is developing the world’s first combination vaccine to protect children against typhoid and shigellosis. Supported by the Gates Foundation, this initiative aims to enhance global immunization efforts and combat deadly enteric diseases in endemic regions effectively.
Share price movement of Zydus:
On March 4, 2025, Zydus Lifesciences Ltd opened at ₹866.45, down 0.13% from its previous close of ₹870.70. The stock reached a high of ₹873.35 (0.80%) and a low of ₹859.15. By 12:35 PM, it traded at ₹871.80, with a market cap of ₹87,723.48 crore.
Zydus to Develop Typhoid-Shigella Vaccine:
Zydus, in collaboration with the Gates Foundation, is set to develop the world’s first combination vaccine against typhoid and shigellosis. This groundbreaking initiative aims to protect children under five from these deadly enteric diseases, enhancing global immunization efforts.
The project, starting in March 2025, involves early-stage development, immunogenicity studies, and regulatory preclinical toxicology research. Zydus will co-develop the vaccine using its WHO-prequalified Typhoid conjugate vaccine (ZyVacTM TCV) alongside a Shigella vaccine from its partner, marking a significant advancement in disease prevention.
With vaccination being the most effective disease-control method, this combination vaccine could provide a sustainable solution for endemic regions. If successful, it will help address overcrowded immunization schedules and contribute to global public health by safeguarding millions of children.
Recent news on Zydus:
As of February 12, 2025, Zydus Lifesciences announced an exclusive agreement with Synthon for a novel 505(B)(2) oncology drug. Zydus will handle NDA submission and commercialization in the U.S., with filing expected in 2026 to enhance patient compliance.
Stock performance of Zydus for Period of 1 week, 6 months, and 1 year:
Zydus Lifesciences Ltd recorded a 1.42% decline in the past week, reflecting short-term pressure. Over six months, the stock dropped 21.9%, while its one-year performance showed an 8.01% decline, highlighting continued challenges in market momentum.
Shareholding pattern of Zydus:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.50% | 7.50% | 5.60% |
| DII | 10.70% | 10.60% | 12.60% |
| Public | 6.90% | 6.90% | 6.80% |
About Zydus:
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) is a global lifesciences company focused on innovation, developing and manufacturing diverse healthcare therapies. With over 27,000 employees, including 1,400 scientists, it aims to transform lives through groundbreaking discoveries and quality healthcare solutions.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
News Author
Aliceblue News Desk
